
Shares of Revolution Medicines RVMD.O up 16% at $125 in after-market trading
Merck's MRK.N shares marginally down 0.6% at $110.30
Peer cancer therapy developer Erasca ERAS.O up 10.2% at $6.40
Merck is in talks to buy cancer drug developer Revolution Medicines, the Financial Times reported on Thursday, citing people familiar with the matter
MRK and RVMD did not immediately respond to Reuters' requests for comment
As of Thursday's close, MRK up 2.2%, RVMD up 4.6% and ERAS up 56.2% YTD